Table 3.
Demographic and clinical variables in patients with and without the 13.8 kDa fragment of A1BG
| Variable | A1BG+ (n = 7) | A1BG− (n = 27) | p-Value |
|---|---|---|---|
| Age (y; mean±SD) | 12.7±2.8 | 9.3±5.8 | 0.149 |
| Sex: male:female | 5:2 | 16:11 | 0.68 |
| Race (%) | 0.56 | ||
| African American | 42.9 (3) | 48.1 (13) | |
| Caucasian | 57.1 (4) | 40.7 (11) | |
| Other | 0 (0) | 11.1 (3) | |
| Pathology (%) | |||
| FSGS | 85.7 (6) | 37 (10) | |
| MCD | 0 (0) | 3.7 (1) | |
| No biopsy | 14.3 (1) | 59.3 (16) | |
| Hypertension (%) | 57.1 (4) | 22.2 (6) | 0.157 |
| Immunosuppressant (%) | 0.005a) | ||
| Steroid | 14.3 (1) | 56 (15) | |
| CNI | 71.4 (5) | 22.2 (6) | |
| MMF | 71.4 (5) | 7.4 (2) | |
| ACEI/ARB (%) | 57.1 (4) | 14.8 (4) | 0.037 |
| Cr (mg/dL) | 2.1±1.9 | 0.8±1.1 | 0.01a) |
| GFR (mL/min/1.73m2) | 54.7±36.3 | 97.7±36.4 | 0.009a) |
| CKD stage | 2.7±1.50 | 1.67±0.92 | 0.06 |
| A1BG level (ng/mL) | 1831.95±1593.68 | 1814.58±1748.17 | 0.96 |
| A1BG/Cr (ng/mg) | 1333.66±622.39 | 3350.53±3515.39 | 0.33 |
| ACR (mg/g) | 17 451.07±6284.66 | 18 433.78±33 381.01 | 0.125 |
a)
Denotes significant difference.